First Time Loading...
E

EuBiologics Co Ltd
KOSDAQ:206650

Watchlist Manager
EuBiologics Co Ltd
KOSDAQ:206650
Watchlist
Price: 12 610 KRW -1.56%
Updated: May 21, 2024
Section:
 

Relative Value

The Relative Value of one EuBiologics Co Ltd stock under the Base Case scenario is 18 562.78 KRW. Compared to the current market price of 12 610 KRW, EuBiologics Co Ltd is Undervalued by 32%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
18 562.78 KRW
Undervaluation 32%
Relative Value
Price
E
Worst Case
Base Case
Best Case

Valuation Multiples

6.6
P/S
P/S
Price to Sales
6.6
vs History
50
vs Industry
59
Median 3Y
7.6
Median 5Y
7
Industry
8.2
Forward
3.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
0
Median 3Y
-33.4
Median 5Y
-21.6
Industry
26.1
Forward
14
More Details
17.4
P/OCF
P/OCF
Price to OCF
17.4
vs History
63
vs Industry
10
Median 3Y
18.9
Median 5Y
23.1
Industry
24.8
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-26.7
Median 5Y
-21.7
Industry
23.4
More Details
4.1
P/B
P/B
Price to Book Value
4.1
vs History
63
vs Industry
23
Median 3Y
4
Median 5Y
5.2
Industry
2.6
More Details
6.7
EV/S
EV/S
Enterprise Value to Sales
6.7
vs History
58
vs Industry
48
Median 3Y
7.6
Median 5Y
7.2
Industry
7.4
Forward
3.7
More Details
13.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
13.6
vs History
57
vs Industry
32
Median 3Y
17.2
Median 5Y
14.5
Industry
9.1
More Details
27.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
27.4
vs History
47
vs Industry
4
Median 3Y
62.8
Median 5Y
26.3
Industry
4.6
Forward
12.4
More Details
60.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
60.1
vs History
4
vs Industry
2
Median 3Y
-105.5
Median 5Y
-80.2
Industry
4.4
Forward
17.3
More Details
17.5
EV/OCF
EV/OCF
Enterprise Value to OCF
17.5
vs History
63
vs Industry
9
Median 3Y
19.1
Median 5Y
23.6
Industry
6.4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-30.8
Median 5Y
-28
Industry
3.8
More Details
3.3
EV/IC
EV/IC
Enterprise Value to IC
3.3
vs History
42
vs Industry
40
Median 3Y
3.3
Median 5Y
2.9
Industry
4.9
More Details

Multiples Across Competitors

Competitors Multiples
EuBiologics Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
EuBiologics Co Ltd
KOSDAQ:206650
459.7B KRW 6.6 -33.1 27.4 60.1
US
Abbvie Inc
NYSE:ABBV
290.6B USD 5.3 48.8 13.7 21.1
US
Amgen Inc
NASDAQ:AMGN
168.7B USD 5.7 44.8 18.8 31.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.2B USD 11.3 28.7 24 25.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
108.8B USD 8.3 28.2 22.8 25.3
AU
CSL Ltd
ASX:CSL
134.3B AUD 6.3 36.2 21.9 27.1
US
Gilead Sciences Inc
NASDAQ:GILD
84.6B USD 3.1 174.8 8.8 11.6
US
Moderna Inc
NASDAQ:MRNA
54B USD 10.5 -9 -10.1 -9
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Biogen Inc
NASDAQ:BIIB
33.7B USD 3.5 28.9 14.7 18.3
KR
Celltrion Inc
KRX:068270
38.7T KRW 17.8 72.3 44.3 61
P/E Multiple
Earnings Growth
KR
E
EuBiologics Co Ltd
KOSDAQ:206650
Average P/E: 57.9
Negative Multiple: -33.1 		N/A
US
Abbvie Inc
NYSE:ABBV
48.8
404%
US
Amgen Inc
NASDAQ:AMGN
44.8
82%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.7
49%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
28.2
47%
AU
CSL Ltd
ASX:CSL
36.2
84%
US
Gilead Sciences Inc
NASDAQ:GILD
174.8
75%
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -9 N/A
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -57.5 N/A
US
Biogen Inc
NASDAQ:BIIB
28.9
155%
KR
Celltrion Inc
KRX:068270
72.3
104%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 139,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.